Table 3.
Associations between ZHX3 expression and clinicopathological features in breast cancer
| Variables | No. of patients | ZHX3 expression
|
P-value | |
|---|---|---|---|---|
| Negative, n (%) | Positive, n (%) | |||
|
| ||||
| Age (years) | ||||
| <45 | 45 | 22 (48.9) | 23 (51.1) | 0.417 |
| ≥45 | 53 | 31 (58.5) | 22 (41.5) | |
| T (primary tumor) | ||||
| T1/T2 | 47 | 26 (55.3) | 34 (44.7) | 0.842 |
| T3/T4 | 51 | 27 (52.9) | 11 (47.1) | |
| N (regional lymph nodes) | ||||
| N0 | 61 | 27 (44.3) | 34 (55.7) | 0.014 |
| N1–N3 | 37 | 26 (70.3) | 11 (29.7) | |
| Stage of tumors | ||||
| I/II | 79 | 37 (46.8) | 42 (53.2) | 0.004 |
| III/IV | 19 | 16 (84.2) | 3 (15.8) | |
| Histological type | ||||
| Non-ductal | 23 | 12 (53.2) | 11 (47.8) | 0.510 |
| Ductal | 75 | 41 (54.7) | 34 (45.3) | |
| Differentiation | ||||
| Well/moderate | 60 | 27 (45.0) | 33 (55.0) | 0.037 |
| Poor | 38 | 26 (68.4) | 12 (31.6) | |
| ER status | ||||
| Negative | 47 | 34 (72.3) | 13 (27.7) | 0.001 |
| Positive | 51 | 19 (37.3) | 32 (62.7) | |
| PR status | ||||
| Negative | 29 | 20 (69.0) | 9 (31.0) | 0.076 |
| Positive | 69 | 33 (47.8) | 36 (52.2) | |
| HER2 status | ||||
| Negative | 59 | 30 (50.8) | 29 (49.2) | 0.535 |
| Positive | 39 | 23 (59.0) | 16 (41.0) | |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.